

~~#~~ 16246

Art Unit: 1646  
Examiner: HAMUD, F.  
Washington, D.C.  
Atty.'s Docket: GRONHOJ-LARSEN=2  
Date: December 21, 1999

Transmitted herewith is an [ ] Amendment [XX] Third Preliminary Amendment

RECEIVED


DEC 27 1999

**TECH CENTER 1600/2900**

f:\user19\wp\n-q\gro825us.cv3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ) Art Unit: 1646  
GRONHOJ-LARSEN, et al. ) Examiner: HAMUD, F.  
Serial No.: 09/101,825 ) Washington, D.C.  
Filed: July 17, 1998 ) December 21, 1999  
For: SYNTHETIC IL-10 ) Docket No.: GRONHOJ-LARSEN=2  
ANALOGUES )



THIRD PRELIMINARY AMENDMENT

Honorable Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

S i r :

Please add the following claims:

*But 72*  
--49. A method of preventing or treating a disease which is preventable or treatable by a substance which has at least one of the following properties,

a) induces inhibition of spontaneous IL-8 production by human monocytes,

b) induces inhibition of IL-1 $\beta$  induced IL-8 production by human peripheral blood mononuclear cells (PBMC),

c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,

*C*  
d) induces chemotactic migration of CD8+ human T lymphocytes in vitro,

e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,

f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,

g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,

h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN- $\gamma$ ,

i) induces the production of IL-4 by cultured normal human CD4+ T cells,

j) reduces the TNF $\alpha$  production in human mixed leukocyte